The review shows the abilities of third-generation luteinizing hormone-releasing hormone (LHRH) antagonists in the treatment of hormone-responsive prostate cancer (PC). Degarelix is presently the most studied and most commonly used LHRH antagonist. It leads to a rapid suppression of testosterone and a reduction in prostate-specific antigen without ranging the level of testosterone and thus prevents the risk of a clinical exacerbation of the disseminated disease. The latest investigations have shown that therapy with degarelix versus LHRH agonists improves the results of PC treatment in relapse-free survival rates. Degarelix is assumed to delay the progression of castration-resistant prostate cancer and to have a more considerable effect on bone metastases, alkaline phosphatase (AP) and follicle-stimulating hormone. The results of clinical trials, which support that it is expedient to use degarelix in second-line hormone therapy or the biochemical progression of the disease during the cycle therapy with LHRH agonists, have been recently obtained. Degarelix shows good tolerability, low toxicity, and no systemic allergic reactions. Thus, the newest-generation LHRH antagonists make novel and important contributions to the anti-androgenic therapy strategy for hormone-responsive PC.